PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
The degradation of overexpressed proteins has emerged as a promising strategy for halting disease progression, particularly in cancer. Traditional small-molecule drugs often face limitations in the elimination of pathogenic proteins, leading to the development of targeted protein degradation (TPD) a...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Taylor & Francis Group
2026-12-01
|
| Σειρά: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.tandfonline.com/doi/10.1080/14756366.2026.2636394 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|